SCYNEXIS Stock

SCYNEXIS Debt / Assets

The Debt-to-Assets Ratio of SCYNEXIS (SCYX) as of Aug 4, 2026 is 0.15. In the previous year, Debt-to-Assets Ratio was 0.09 — a change of 59.48% (higher).

Debt / Assets

0.15

YoY

59.48%

Last updated:

Debt-to-Assets Ratio of SCYNEXIS is 2026 0.15 . Debt-to-Assets Ratio of SCYNEXIS was 2025 0.09 . It decreases by 59.48% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Debt-to-Assets Ratio of SCYNEXIS is 0.15 in 2026.

Debt-to-Assets Ratio of SCYNEXIS changed from 0.09 to 0.15, representing a 59.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SCYNEXIS

All Key Metrics — SCYNEXIS